NYSE:IQVIqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IQV stock has increased by 27.7% and is now trading at $160.15.
View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) announced its quarterly earnings results on Wednesday, July, 22nd. The medical research company reported $1.18 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.12. The medical research company earned $2.52 billion during the quarter, compared to the consensus estimate of $2.41 billion. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. During the same quarter in the previous year, the firm earned $1.53 EPS.
View Iqvia's earnings history.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided EPS guidance of $6.10-6.30 for the period, compared to the Thomson Reuters consensus estimate of $5.87. The company issued revenue guidance of $11.0-11.1 billion, compared to the consensus revenue estimate of $10.73 billion.

17 Wall Street analysts have issued 12-month price objectives for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they expect Iqvia's share price to reach $165.00 in the next year. This suggests a possible upside of 3.0% from the stock's current price.
View analysts' price targets for Iqvia.

Media headlines about IQV stock have been trending neutral on Wednesday, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iqvia earned a news impact score of 0.4 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Iqvia.

Iqvia saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 2,490,000 shares, a decline of 15.3% from the June 30th total of 2,940,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.3% of the shares of the company are short sold.
View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL) and Accenture (ACN).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.67%), Morningstar Investment Services LLC (0.33%), Raymond James & Associates (0.31%), First Trust Advisors LP (0.26%), Hardman Johnston Global Advisors LLC (0.19%) and Ardevora Asset Management LLP (0.17%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub.
View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Sumitomo Mitsui Trust Holdings Inc., State of Michigan Retirement System, State of Alaska Department of Revenue, Robeco Institutional Asset Management B.V., Arizona State Retirement System, Nisa Investment Advisors LLC, and Ardevora Asset Management LLP. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Veracity Capital LLC, First Trust Advisors LP, Raymond James & Associates, Raymond James Financial Services Advisors Inc., Envestnet Asset Management Inc., Dupont Capital Management Corp, Mn Services Vermogensbeheer B.V., and Pacer Advisors Inc..
View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $160.15.

Iqvia has a market capitalization of $30.63 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

The official website for Iqvia is www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]